ArticleSleep2026
Relation of sleep quality, sleep disturbance, and hydroxyurea use to neurocognitive function in youth living with sickle cell disease.
Article in Sleep, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
STUDY
objectivesNeurocognitive deficits are present in youth with sickle cell disease (SCD) without notable neurological complications. Sleep quality and disturbances can negatively impact their neurocognition and quality of life. This study aimed to assess the relationship between sleep and neurocognitive outcomes in youth with SCD, considering disease-related risks, protective factors, socioeconomic status, and the impact of hydroxyurea (HU).
methodsParticipants were selected from a retrospective clinical database of youth with SCD. All youth completed either a polysomnography (PSG) or sleep questionnaire and a neuropsychological evaluation to assess cognitive skills, including verbal comprehension, working memory, cognitive flexibility (CF), attention, and processing speed (PS).
resultsThe sample included individuals with sleep questionnaire ratings (n = 42) and individuals with PSG (n = 33). The primary aim indicated that CF decreased (B = -4.269, p < .001) and caregiver-rated executive dysfunction increased (B = 8.565, p = .020) for individuals with higher sleep-related impairments. In the exploratory aim, PSG data revealed that CF (B = -3.082, p = .005) and PS (B = -2.171, p = .008) decrease for each 1% increase in time spent under 90% oxygen saturation (pTST SpO2 < 90%). HU was not a significant moderator in the relationship between sleep and neurocognitive performance.
conclusionsThe study's primary findings highlight that sleep-related impairments are significantly related to neurocognitive challenges in youth with SCD. Exploratory PSG analysis supports these findings, linking pTST SpO2 < 90% and cognition. Future research on sleep interventions is essential for improving neurocognitive functioning in this population. Statement of Significance This study highlights the significant impact of sleep-related impairments on neurocognitive outcomes in youth living with sickle cell disease (SCD) despite the absence of major neurological complications. An assessment of sleep quality and nocturnal oxygen saturation has a bidirectional impact on the disease course and neurocognitive outcomes of youth living with SCD. Neurocognitive challenges can have lasting effects on academic performance, transition readiness, and quality of life. Most research focuses on neurocognitive and disease-related effects of severe complications. This study gives insight into the impact and needs of youth living with SCD without major complications. Thus, addressing the risk of sleep-related impairments through targeted interventions may improve neurocognitive outcomes and reduce the impact of other health complications associated with SCD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.